{"title":"在一项真实世界的研究中，55岁以上接受同种异体造血干细胞移植的恶性血液病患者的移植相关死亡率没有显示出显著差异","authors":"Jing Liu, Tingting Han, Haixia Fu, Yuhong Chen, Wei Han, Yao Chen, Yuan-yuan Zhang, Lanping Xu, Yu Wang, Xiaodong Mo, Fengrong Wang, Yuqian Sun, Xiaojun Huang, Xiaohui Zhang","doi":"10.1111/ctr.70192","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Transplantation related mortality (TRM) remains an issue, particularly in older patients with hematological malignancies. In order to assess the TRM and the feasibility of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in older patients, we collected data from a total of 251 patients aged 55–70 years with acute hematological malignancies who received allo-HSCT from April 19, 2011 to June 28, 2022 in our hospital. With the median follow-up of 637 days, the cumulative incidence of TRM for patients above 55 years on Day 100, 1 year, and 2 years was 6.0%, 21.2%, and 26.7%, respectively. Forty-three (17.1%) patients died of TRM, of whom 11 patients died within 100 days after allo-HSCT, including two due to TMA, two due to aGVHD and TMA simultaneously, one due to capillary leak syndrome, and six due to infection. The cumulative incidence of TRM on Day 100, 1 year, and 2 years between the group aged 55–59 and 60–70 years did not show significant differences. Through a Cox regression analysis, platelet engraftment failure, conditioning regimen, grade 3–4 aGVHD, and cytomegalovirus disease were determined as risk factors for TRM in older patients. In conclusion, allo-HSCT is a feasible option for older patients with hematological malignancies.</p>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transplantation Related Mortality Did Not Show Significant Differences in Patients Aged Above 55 Years With Hematological Malignancies Receiving Allogeneic Hematopoietic Stem Cell Transplantation in a Real-World Study\",\"authors\":\"Jing Liu, Tingting Han, Haixia Fu, Yuhong Chen, Wei Han, Yao Chen, Yuan-yuan Zhang, Lanping Xu, Yu Wang, Xiaodong Mo, Fengrong Wang, Yuqian Sun, Xiaojun Huang, Xiaohui Zhang\",\"doi\":\"10.1111/ctr.70192\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Transplantation related mortality (TRM) remains an issue, particularly in older patients with hematological malignancies. In order to assess the TRM and the feasibility of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in older patients, we collected data from a total of 251 patients aged 55–70 years with acute hematological malignancies who received allo-HSCT from April 19, 2011 to June 28, 2022 in our hospital. With the median follow-up of 637 days, the cumulative incidence of TRM for patients above 55 years on Day 100, 1 year, and 2 years was 6.0%, 21.2%, and 26.7%, respectively. Forty-three (17.1%) patients died of TRM, of whom 11 patients died within 100 days after allo-HSCT, including two due to TMA, two due to aGVHD and TMA simultaneously, one due to capillary leak syndrome, and six due to infection. The cumulative incidence of TRM on Day 100, 1 year, and 2 years between the group aged 55–59 and 60–70 years did not show significant differences. Through a Cox regression analysis, platelet engraftment failure, conditioning regimen, grade 3–4 aGVHD, and cytomegalovirus disease were determined as risk factors for TRM in older patients. In conclusion, allo-HSCT is a feasible option for older patients with hematological malignancies.</p>\\n </div>\",\"PeriodicalId\":10467,\"journal\":{\"name\":\"Clinical Transplantation\",\"volume\":\"39 6\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-05-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70192\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70192","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Transplantation Related Mortality Did Not Show Significant Differences in Patients Aged Above 55 Years With Hematological Malignancies Receiving Allogeneic Hematopoietic Stem Cell Transplantation in a Real-World Study
Transplantation related mortality (TRM) remains an issue, particularly in older patients with hematological malignancies. In order to assess the TRM and the feasibility of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in older patients, we collected data from a total of 251 patients aged 55–70 years with acute hematological malignancies who received allo-HSCT from April 19, 2011 to June 28, 2022 in our hospital. With the median follow-up of 637 days, the cumulative incidence of TRM for patients above 55 years on Day 100, 1 year, and 2 years was 6.0%, 21.2%, and 26.7%, respectively. Forty-three (17.1%) patients died of TRM, of whom 11 patients died within 100 days after allo-HSCT, including two due to TMA, two due to aGVHD and TMA simultaneously, one due to capillary leak syndrome, and six due to infection. The cumulative incidence of TRM on Day 100, 1 year, and 2 years between the group aged 55–59 and 60–70 years did not show significant differences. Through a Cox regression analysis, platelet engraftment failure, conditioning regimen, grade 3–4 aGVHD, and cytomegalovirus disease were determined as risk factors for TRM in older patients. In conclusion, allo-HSCT is a feasible option for older patients with hematological malignancies.
期刊介绍：
Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored.
Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include:
Immunology and immunosuppression;
Patient preparation;
Social, ethical, and psychological issues;
Complications, short- and long-term results;
Artificial organs;
Donation and preservation of organ and tissue;
Translational studies;
Advances in tissue typing;
Updates on transplant pathology;.
Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries.
Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
